Correlation of Thyroglobulin Antibodies (TgAb) With Clinicopathological Features and Unfavorable Efficacy of 131I Ablation in Papillary Thyroid Carcinoma (PTC)
Authors' conclusion
TgAb positivity is associated with increased risk of multiple foci and unfavorable efficacy of 131I ablation in PTC.
Study context
- Population
- PTC patients who underwent total thyroidectomy and subsequent 131I ablation
- Participants
- 548 patients
- Exposure
- Preoperative TgAb-positive vs TgAb-negative
- TgAb-positiven = 157
- TgAb-negativen = 391reference
- Outcome
- Efficacy of 131I ablation and its risk factors; clinicopathological features by TgAb status
Main finding
As reported in the abstract
Nonefficacy of 131I ablation (logistic regression)
- TgAb positivity positively correlated with nonefficacy, OR
- 2.248
- Longer surgery-to-131I interval positively correlated with nonefficacy, OR
- 1.012
- Initial 131I dosage > 100 mCi positively correlated with nonefficacy, OR
- 3.128
- P for these associations
- P < .05
- Effective group
- 460 cases, 84.94%
- Noneffective group
- 88 cases, 16.06%
Observational data: associations, not effects.
Further findings
Clinicopathological features, TgAb-positive vs TgAb-negative
- Logistic regression: TgAb positivity positively correlated with multifocality
- P < 0.05
- TgAb-positive younger, more females, TPOAb positivity, multiple foci, coexistent Hashimoto thyroiditis, increased TSH; reduced FT4, FT3 and BRAF positivity (all P < .05)
Original publication
Correlation of TgAb With Clinicopathological Features and Unfavorable Efficacy of 131I Ablation in PTC. J Clin Endocrinol Metab. Published 7 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →